Literature DB >> 24717110

Complete remission of CD30-positive diffuse large B-cell lymphoma in a patient with post-transplant lymphoproliferative disorder and end-stage renal disease treated with single-agent brentuximab vedotin.

Brian T Hill1, Raymond R Tubbs, Mitchell R Smith.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 24717110     DOI： 10.3109/10428194.2014.911865

Source DB:  PubMed          Journal:  Leuk Lymphoma        ISSN： 1026-8022


× No keyword cloud information.
  3 in total

1.  Prevalence and clinicopathologic features of CD30-positive de novo diffuse large B-cell lymphoma in Chinese patients: a retrospective study of 232 cases.

Authors:  Qi-Xing Gong; Ting-Xun Lu; Chong Liu; Zhen Wang; Jin-Hua Liang; Wei Xu; Jian-Yong Li; Zhi-Hong Zhang; Qi Chen
Journal:  Int J Clin Exp Pathol       Date:  2015-12-01

Review 2.  Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review.

Authors:  Garrett K Berger; Ali McBride; Stephanie Lawson; Kelsey Royball; Seongseok Yun; Kevin Gee; Irbaz Bin Riaz; Ahlam A Saleh; Soham Puvvada; Faiz Anwer
Journal:  Crit Rev Oncol Hematol       Date:  2016-11-21       Impact factor: 6.312

3.  Diagnostic and therapeutic challenges of EBV-positive mucocutaneous ulcer: a case report and systematic review of the literature.

Authors:  Toni K Roberts; Xueyan Chen; Jay Justin Liao
Journal:  Exp Hematol Oncol       Date:  2016-04-27
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.